Loading data for SLN — first visit, this takes a few seconds.
Silence Therapeutics (SLN)
NasdaqGM: SLN
· Real-Time Price · USD
13.72
-0.25 (-1.79%)
At close: Aug 14, 2026, 8:00 PM
13.72
+0.00%
After-hours: 7:34 PM
Silence Therapeutics (SLN) Stock Price, Analysis & Data
-1.79% (1D)
No data available
| Bid | n/a |
| Market Cap | 648.22M |
| Revenue (ttm) | 615K |
| Net Income (ttm) | -59.95M |
| Beta | 1.41 |
| EPS (ttm) | -1.29 |
| PE Ratio (ttm) | n/a |
| Forward PE | -17.93 |
| P/B (ttm) | 10.40 |
| P/S (ttm) | 1054.02 |
| Earnings Date | Nov 5, 2026 |
| Ask | n/a |
| Volume | 823,122 |
| Avg. Volume (20D) | 890,395 |
| Open | 14.01 |
| Previous Close | 13.97 |
| Day's Range | 13.44 - 14.22 |
| 52-Week Range | 4.19 - 17.58 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SLN
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN36...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 8, 2020
Employees 88
Stock Exchange NasdaqGM
Ticker Symbol SLN
Financial Performance
In 2025, Silence Therapeutics's revenue was 559K, a decrease of -98.71% compared to the previous year's 43.26M. Earnings were -88.61M, an increase of 95.57%.
Financial StatementsEarnings Surprise
Silence Therapeutics has released their quarterly earnings on Aug 10, 2026:
Silence Therapeutics is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2